Business Wire

Pioneer Announces Purchase of CryptoPunk 8869

4.11.2021 21:00:00 EET | Business Wire | Press release

Share

Pioneer Media Holdings Inc. (“Pioneer” or the “Company”) purchased CryptoPunk 8869.

https://www.larvalabs.com/cryptopunks/details/8869

Accessories:

- blue bandana

- muttonchops

- regular shades.

"We are excited about Web3" said Mike Edwards, CEO of Pioneer. "The real question is how do you dive in? We looked for guidance from the community. Answer = Step 1 is buy a JPEG!"

Transaction Details

Pioneer acquired CryptoPunk 8869 for 100.25 ETH (US$ 433,703.58).

The Company provides the following update on what it sees trending in this space.

Web3 is otherwise referred to as the ownership economy because the token economic models reward participation and creativity. NFTs in particular enable coordination around the shared ownership of art and beyond; an investment in this space is more about joining a community than investing in a traditional company and this is why Pioneer decided to acquire a piece of the most iconic collection to date, the CryptoPunk.

NFTs have captured the spirit of the private markets. In the past month, SoRare (private) and Dapper Labs (private) have raised US$680M at a US$4.3B valuation and US$250M at a US$7.6B valuation respectively. In addition, Axie Infinity maker Sky Mavis (private) and Animoca (private) respectively raised US$152M at a US$3B valuation and US$65M at a US$2.2B valuation. Cumulatively that implies +US$1B in fresh capital at a combined market cap of +US$17B for four NFT privates in under a month. NFT sales in Q3 hit US$10.7B up from US$1.3B in Q2 and from US$28M in the same quarter of 2020

While meme stocks have captured the spirit of the public markets. In 2021 ‘Meme stocks’ like GameStop and AMC were completely changed fueled by retail investor euphoria driven by Reddit memes. GameStop raised ~US$1.1 billion after surging +1,200% and AMC raised ~US$1.2 billion driven by the share price appreciation through Reddit memes.

CryptoPunks are one of the primary NFT status symbols in crypto. A CryptoPunk owner refused a US$9.5 million bid for his asset in October, a four year old CryptoPunk 1422 was just sold for US$2 million, and recently a half a billion dollar transaction enabled by a flash loan for Punk 9998

8869, a Punk, a NFT, and a meme stock: Pioneer combines the meme stock and NFT element by becoming the first publicly tradable company to embody a CryptoPunk and allow for fractionalized equity ownership of that CryptoPunk. Through equity ownership in Pioneer, investors will become fractional owners of Punk 8869, a public markets first.

The Pioneer Plan

  • Pioneer will be the first true listed Web3 investment company focused on NFT gaming and assets. Building off of its success in mobile gaming (LEAF), eSports (GILD/Dynasty/Paidia) and its foundational investment in NFT Investments.
  • Pioneer will invest and acquire the best brands, teams and assets in the space.

About Pioneer Media Holdings Inc.

Pioneer is the first publicly traded issuer that actively invests in a diversified portfolio of early-stage to mid-level companies in Web3 including NFTs and NFT gaming, together with investments in esports, and mobile gaming. Pioneer’s management team leverages its global network to democratize access to investments not normally available to the retail investor community.

The current Pioneer portfolio includes investments such as: Leaf Mobile Inc. (TSX: LEAF), a leading free-to-play mobile games group; Guild eSports plc (LON: GILD), a global eSports business headquartered in London whose lead investor is David Beckham; Dynasty eSports Pte Ltd, creators of the world’s leading white-label Gaming Ecosystem Management solution, partnering exclusively on a B2B basis with Tier 1 telco's and large media organisations; NFT Investments plc, a London based investment company focused on non-fungible tokens (“NFTs”), and Kodoku Studios Ltd., London based team that stands at the forefront of the exciting new NFT gaming genre Pioneer provides capital, experience, and support to these emerging market leaders while building shareholder value. Additional information about Pioneer is available at www.sedar.com.

ON BEHALF OF PIONEER MEDIA HOLDINGS INC.

Mike Edwards

CEO & Director

Neither the Canadian Securities Exchange nor any Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Cautionary Statements

Forward Looking Statements

This news release may contain “forward-looking” statements and information relating to the Company, the funds to be raised, and the use of any such funds that are raised, that are based on the beliefs of Company management, as well as assumptions made by and information currently available to Company management. There is no assurance the Company will be able to complete the placement on the terms as outlined above, or at all. The Company does not undertake to update forward‐looking statements or forward‐looking information, except as required by law.

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Mike Edwards
Via Tancredi
+44 203 434 2330

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Opzelura ® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 14:30:00 EEST | Press release

Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids (TCSs) and topical calcineurin inhibitors (TCIs) are inadequate or inappropriate. “AD is a chronic skin condition that can have a significant impact on daily life. The positive CHMP opinion for Opzelura marks meaningful progress toward bringing the first non-steroidal topical JAK treatment option to adults in Europe with moderate AD for whom standard topical therapies have failed,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved by the European Commission, Opzelura could help address an important gap for patients who have limited treatment options when TCSs and TCIs are inadequate or inappropriate.” The positive CHMP o

Datroway ® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 14:00:00 EEST | Press release

Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the TROPION-Breast02phase 3 trial, which werepresented at the 2025 European Society for Medical Oncology Congress and published in Annals of Oncology. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In TROPION-Breast02, Datroway demonstrated a

DAYBU ® (trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 13:49:00 EEST | Press release

Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating condition," said Catherine Owen Adams, Acadia’s Chief Executive Officer. “Our commitment is to make a meaningful difference in the lives of patients, caregivers, and the wider Rett com

HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 12:18:00 EEST | Press release

HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi

Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 11:28:00 EEST | Press release

Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye